The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy

Pancreatic ductal adenocarcinoma (PDAC) has a 5‐year survival rate of less than 4% and desperately needs novel effective therapeutics. Integrin αvβ6 has been linked with poor prognosis in cancer but its potential as a target in PDAC remains unclear. We report that transcriptional expression analysis...

Full description

Saved in:
Bibliographic Details
Published in:J Pathol
Main Authors: Reader, Claire S, Vallath, Sabari, Steele, Colin W, Haider, Syed, Brentnall, Adam, Desai, Ami, Moore, Kate M, Jamieson, Nigel B, Chang, David, Bailey, Peter, Scarpa, Aldo, Lawlor, Rita, Chelala, Claude, Keyse, Stephen M, Biankin, Andrew, Morton, Jennifer P, Evans, TR Jeffry, Barry, Simon T, Sansom, Owen J, Kocher, Hemant M, Marshall, John F
Format: Artigo
Language:Inglês
Published: John Wiley & Sons, Ltd 2019
Subjects:
Original Papers
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6852434/
https://ncbi.nlm.nih.gov/pubmed/31259422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/path.5320
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items